Objectives. Objectives. Clinically Significant Drug Interactions: the Antimicrobial Version 4/20/2018
|
|
- Earl Lawson
- 5 years ago
- Views:
Transcription
1 Clinically Significant Drug Interactions: the Antimicrobial Version Dr. Barr declares no conflicts of interest, real or apparent, and no financial interests in any company, product or service mentioned in this program, including grants, employment, gifts, stake holdings and honoraria. Viki Barr PharmD, BCPS-AQ ID Assistant Professor Rosalind Franklin University Objectives At the completion of this activity, the pharmacist will be able to: Describe the mechanisms of drug interactions Explain the severity of the interaction and how it applies to a patient Outline clinical decisions using information on interactions between commonly used medications and antimicrobials Objectives At the completion of this activity, the technician will be able to: Identify potential risk factors for drug interactions Describe the mechanisms of drug interactions Discuss the drug-drug interaction severity rating systems 1
2 Pharmacists Under Fire Pharmacists Under Fire In December 2016 The Chicago Tribune published that it tested 255 pharmacies to see how often stores would dispense risky drug pairs without warning patients 52% of the tested pharmacies sold the medications without mentioning the potential interaction Epidemiology of Drug (drug) Interactions True incidence difficult to determine Data for drug-related hospital admissions do not separate out drug interactions, focus on ADRs Most data are in the form of case reports Missing or incomplete information 2
3 Risk Factors for Drug Interactions Drug Interactions Poly pharmacy Multiple prescribers Genetic makeup Specific populations Geriatric, obese, critically ill, transplant, etc Disease Specific HIV, renal dysfx, hepatic dysfx, etc Narrow therapeutic index drugs Warfarin Length of hospital stay Lack of pharmacist evaluation Definition: The pharmacologic or clinical response to the administration of a drug combination different from that anticipated from the known effects of the two agents when given alone May be harmful: toxicity, reduced efficacy May be beneficial: Synergistic combinations, pharmacokinetic boosting, increased convenience, reduced toxicity, cost reduction Bjerrum L, et al. EurJ Gen Pract. 2008;14(1):23-29 Janovic SM, et al. J of Crit Care. 2018(43);1-6. Types of Drug Interactions or Mechanisms Pharmacokinetic Drug Interactions Pharmacokinetic What the body does with the drug One drug alters the concentration of another Usually mediated by cytochrome P450 Pharmacodynamic Related to the drug s effects in the body One drug modulates the pharmacologic effect of another: additive, synergistic, or antagonistic Drug absorption Drug metabolism (biotransformation) CYP3A4, CYP2D6, CYP2C9 Transport of the drug inside the body Drug displacement (protein-binding) Drug excretion 3
4 Level of Severity of Interactions Level of Severity of Interactions- Micromedex Many different sites available for level of severity classification Micromedex Lexi-Comp Clinical Pharmacology Typically range from levels 1 to 5 Severe interactions Moderate interactions Minor interactions Cautionary interactions Clinically not significant interactions or not established lindfranklin.edu:showdruginteractionsresults Risk Rating Action Description A B C D X No Known Interaction No Action Needed Monitor Therapy Consider Therapy Modification Avoid Combination Adapted from: Information/Lexi-Interact-Fields Data have not demonstrated either PK/PD interactions between the specified agents Data demonstrate that the specified agents may interact with each other, but there is little to no evidence of clinical concern Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The benefits of concomitant use of these two medications usually outweigh the risks. An appropriate monitoring plan and\or dosage adjustments may be necessary. Data demonstrate that the two medications may interact with each other in a clinically significant manner. A patient-specific assessment must be conducted to determine whether the benefits of concomitant therapy outweigh the risks. Specific actions must be taken in order to realize the benefits and/or minimize the toxicity resulting from concomitant use of the agents. These actions may include aggressive monitoring, empiric dosage changes, choosing alternative agents. Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The risks associated with concomitant use of these agents usually outweigh the benefits. Generally considered contraindicated. Self Assessment Question What are risk factors for exhibiting drug interactions (DI s)? A. Poly pharmacy B. Genetic makeup C. Specific populations D. Narrow therapeutic index drugs E. All the above 4
5 I Have a Cough Case Applications 67 yof came in with a cough where she was prescribed azithromycin 500mg PO x 5 days. She is here now to pick up her new script. Current med list: Esomeprazole 40mg daily Diltiazem XR 240mg daily Lisinopril 10mg daily Fluoxetine 40mg daily Lets Run an DI Check CI use of fluoxetine and azithromyin So what would you do? DC the fluoxetine DC the azithromycin DC both medications Keep both medications and dispense QT Prolongation Prolonged QTcis a heart rhythm condition that can potentially cause fast, chaotic heartbeats A normal QTcinterval generally ranges between milliseconds People with long QTc(QT interval 500 milliseconds) have potentially dangerous QT prolongation Lexicomp Drug Interactions. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: Source: MayoClinic.org 5
6 Risk Factors for QT Prolongation Age >65 Female gender Bradycardia Left ventricular failure Recent cardioversion Electrolyte abnormalities Hypomagnesemia, hypokalemia, hypocalcemia Higher concentrations of one or more QTprolonging drugs Genetic predisposition Azithromycin and Risk Cardiovascular Death Retrospective cohort of individuals in the Tennessee Medicaid Program to detect an increased risk of death ( ) Patient were on: Azithromycin Amoxicillin Ciprofloxacin Levofloxacin Roden DM. N EnglJ Med. 2004;350: Yap YG, Camm AJ. Heart. 2003;89: Drew BJ. J Am CollCardiol, 2010, 55(9): Ray WA et al. NEJM 336(20): Azithromycin and Risk Cardiovascular Death Outcomes 5 day course of azithromycin compared to no ABX risk of CV death (HR, 2.88; 95% CI, 1.79 to 4.63; P<0.001) Pts on amoxicillin has no increased risk of death Azithromycin associated with a small absolute increase in the risk of CV death (47 cases per 1 million) Specifically in patients with CV disease (245 cases in 1 million The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ from levofloxacin After 5 day course, even with long T½, risk of cardiovascular death did not persist Azithromycin and Risk Cardiovascular Death In another retrospective population study of US veterans Azithromycin shown to significantly increase the risk of mortality and arrhythmia on days 1 to 5, but not on days 6 to 10 after dispensing the prescription Some conflicting data: Two large retrospective cohort studies did not demonstrate an increased risk of CV events Including all-cause mortality or CV death The implications of these data have yet to be determined Ray WA et al. NEJM 336(20): Rao GA, et al. Ann Fam Med. 2014;12(2): Mortesen EM, et al. JAMA. 2014;311(21): Svanstrom H. et al. NEJM. 2013;368(18):
7 Azithromycin and Risk Cardiovascular Death So what should we take from these studies: In patient with heart defect or on other QT prolonging agent, be more cautious In the hospital-get EKG Outpatient- depends where they are getting med from May want to consider getting baseline if outpatient and has more risk factors Back to the Patient 67 yof came in with a cough where she was prescribed azithromycin 500mg PO x 5 days. She is here now to pick up her new script. Current med list: Esomeprazole 40mg daily Diltiazem XR 240mg daily Lisinopril 10mg daily Fluoxetine 40mg daily What would you do? Self Assessment Question Which of the following are risk factors associated with taking azithromycin QTc prolongation? A. Advanced age B. Heart defect C. Addition of other QT prolonging agent D. All the above Still Have a Cough. Same 67 yof came in with a cough where she was prescribed moxifloxacin 400mg PO x 10 days and prednisone 60mg taper over 2 weeks She is here now to pick up her new scripts. Current med list: Esomeprazole 40mg daily Diltiazem XR 240mg daily Lisinopril 10mg daily Fluoxetine 40mg daily MVI daily 7
8 Lets Run an DI Check Fluoroquinolones (FQ) and QTc Prolongation CI use of moxifloxacin and fluoxetine Monitor therapy for moxifloxacin and prednisone So what would you do? DC fluoxetine DC moxifloxacin DC prednisone DC all medications Keep all medications and dispense Other suggestions? Lexicomp Drug Interactions. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: FQ share the potential to block the cardiac voltage-gated potassium channels Higher the FQ dose and serum AUCs, the higher the QT prolongation risk and subsequently the risk of Td The degree to which FQ block cardiac K+ channels and thereby cause QT prolongation varies by agent Moxi> levo> cipro Rubinstein E. JAC. 2002;4(1): Lexicomp Drug Interactions. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: Fluoroquinolones (FQ) and QTc Prolongation MVI s with Fluoroquinolones Case-control analysis that included 605,127 patients receiving treatment for respiratory conditions 1838 cases of serious arrhythmia were identified The rate of serious arrhythmia was elevated with current fluoroquinolone use (RR 1.76, 95% CI ), particularly with new current use Showed ciprohad as high of risk as moxi Nationwide populationbased study in Taiwan Compared the risks of ventricular arrhythmia and CV death within 7 days after initiation of a macrolide, FQ, or amoxicillin-clavulanate Observed an increase in risk of ventricular arrythmia with FQ and azithromycin FQ forms a chelate with the cations resulting in inactive antimicrobials Interaction most significant with aluminum and magnesium ions Lesser with calcium ions The reduction in FQ absorption can significantly affect Cmax and % bioavailability Inhibiting the therapeutic effectiveness Space out 2 hrsbefore MVI or 6 hrsafter Lapi F, et al. CID. 2012;55(11) Chou HW, et al. CID (4): Shimada J, etal. AAC. 1993;36: Lexicomp Drug Interactions. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: 8
9 Steroids and Fluoroquinolones Patients are at an elevated risk of tendinitis and tendon rupture when taking systemic FQ and a steroid together Even more elevated in: Older patients (> 60) receiving steroids Heart, lung, and kidney transplant recipients Achilles Tendon Rupture (ATR) The Achilles tendon is a strong fibrous cord that connects the muscles in the back of your calf to your heel bone Source: MayoClinic.org Overstretch it can cause it to rupture Mainly occurs in people playing recreational sports, but it can happen to anyone Lapi F, et al. CID. 2012;55(11) Chou HW, et al. CID (4): Lexicomp Drug Interactions. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: Risk Factors for Achilles Tendon Rupture Drugs Advanced age Decline of physical activity Peak incidence middle age Male gender (2x) Obesity Disease specific: Renal insufficiency Rheumatological diseases (specifically RA) Hyperpaprathyroidism DM Hyperlipidemia Achilles Rupture with FQ and Steroids Proposed mechanisms: FQ: Mice and rat tendons exhibit hypoxic free radical damage which can lead to tendon weakening Human case reports typically within 90 days of start of a FQ (but reported up to a year) Steroids: Injection of steroids into the tendons of rats shown to cause tendon necrosis In humans shown to cause massive hypertrophy of muscles without causing corresponding strengthening of the associated tendons Seeger JD, et al. Pharmacoepiand Drug Safety. 2006;15: MauffulliN, et al. J Bone SurgAm. 1998;81: Seeger JD, et al. Pharmacoepiand Drug Safety. 2006;15:
10 Achilles Rupture with FQ and Steroids Many case reports reporting incidences of ATR with one of both drugs Vander Linden and colleagues found: Steroids with FQ and > 60 yrs of age had a 5 fold increased risk of ATR Wise and colleagues looked at impact of age, sex, obesity and steroid and FQ use and ATR Steroid with FQ with increased age and non obese at increased risk Also found DM and those with renal failure or receiving HD may be in increased risk Achilles Rupture with FQ and Steroids So what should we take from these studies: Combination of FQ and steroids significantly increased the risk of ATR specifically in patients with: Elderly Renal insufficiency with or without HD DM Van der Linden PD, et al. Arch Intern Med. 2003;163: Wise BL, et al. Am J of Medicing. 2012;125: Back to the Patient Same 67 yof came in with a cough where she was prescribed moxifloxacin 400mg PO x 10 days and prednisone 60mg taper over 2 weeks She is here now to pick up her new scripts. Current med list: Esomeprazole 40mg daily Diltiazem XR 240mg daily Lisinopril 10mg daily Fluoxetine 40mg daily MVI daily What would you do?? Self Assessment Question Which of the following statements is true regarding FQ s and MVI s? A. A MVI should always be discontinued when taking a FQ B. The interaction will significantly affect the bioavailability if the FQ C. If taking a MVI the FQ should taken 2 hrs before the MVI or 2 hrsafter 10
11 Self Assessment Question Which of the following are considered risk factors for a tendon rupture? A. Female gender B. Advanced age C. Increased physical activity D. Underweight Can I Please Have my Antibiotic??? 33 yof comes to your pharmacy with a prescription for augmentin875mg BID x 10 days for a UTI Current med list: MVI daily Ortho-tri cyclen Lo daily Lets Run an DI Check No action needed, right? Summary: Penicillinsmay diminish the therapeutic effect of Estrogen Derivatives Antibiotics (PCN) and Oral Contraceptives (OC) 1994, the British Dental Journal published a paper reviewing the possible interactions between antibiotics and OCs Patient needed to be warned that ABX given may interfere with the OC effects and that additional contraceptive methods should be used while taking the antibiotics and for 7 days after stopping Lexicomp Drug Interactions. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: Gibson J, et al. Br Dent J. 1994;177:
12 Mechanism of Penicillin's Decreasing Efficacy of Birth Control Penicillin's can alter intestinal flora Wiping out our normal flora in our gut Possibly leading to lower estrogen reabsorption Decreased oral combination contraceptive efficacy Recent Literature on Interaction Helms and colleagues retrospectively examined the effect of commonly prescribed oral antibiotics on the failure rate of Ocs 365 patients use of combination 263 also provided "control" data (during the times they used OCs alone) Additional 162 patients provided control data only 5 pregnancies occurred in 311 woman-years of combined antibiotic/oc exposure (1.6% per year failure rate) vs 12 pregnancies in 1245 woman-years of exposure (0.96% per year) for the 425 control patients This difference was not significant (p = 0.4), 95% CI (-0.81, 2.1) 1-3% failure rate Hemls SE, et al. J Am AcadDerm. 1997;36(5.1): Recent Literature on Interaction PK study by Dogteromand colleagues Evaluated interaction with Nuvaringwith and without amoxicillin and doxycycline Showed no interaction between estrogen containing OCs and oral amoxicillin and doxycycline Stated contraceptive efficacy would also be unaffected Back to Our Patient 33 yof comes to your pharmacy with a prescription for augmentin875mg BID x 10 days for a UTI Current med list: MVI daily Ortho-tri cyclen Lo daily So can she have her antibiotic, or do we need recommend something? Dogteron P, et al. Clin Pharmacokinet. 2005;44(4):
13 Two Patients Same Concern? Lets Run a DI Check 35 yo M currently admitted for a severe SSTI to be started on Linezolid 600mg BID PMH: Depression, back pain (post spine surg) Current meds: Sertraline 100mg D Tramadol 100 q 6 h 65 yo M currently admitted for a severe SSTI to be started on Linezolid 600mg BID PMH: Depression, chronic pain (NSLC), CHF, DM Current meds: Sertraline 50 mg D Fentanyl patch 25mg Lasix 20 mg D Metoprolol 100mg D Lisinopril 20mg D Metformin 1000mg BID Glipizide 5mg D 35 yrold F So what would you do? 65 yrold F Lexicomp Drug Interactions. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: Serotonin Syndrome Potentially life-threatening ADR that results from: Therapeutic drug use Prescriptions: SSRI, SNRI, MAOIs, analgesics (fentanyl, meperidine, tramadol), antipsychotics, anticonvulsants, antiparkinsonian agents, dextromethorphan, ondansetron, trazodone, linezolid etc Illicit drugs: LSD, cocaine Herbals: St. John s wort and ginseng Intentional self-poisoning Inadvertent interactions between drugs Boyer EW, et al.nejm. 2005;352: Symptoms of Serotonin Syndrome Clinical manifestations from barely noticeable to lethal Clinical Triad Mental-status changes Autonomic hyperactivity Neuromuscular abnormalities Boyer EW, et al.nejm. 2005;352:
14 Incidence of Serotonin Syndrome Performing a rigorous epidemiologic assessment of the serotonin syndrome is difficult More than 85 % of physicians are unaware of the serotonin syndrome as a clinical diagnosis Assessment has relied on post-marketing surveillance studies Incidence is thought to mirror the increasing number of proserotonergic agents Surveillance Study Reported 26,733 incidences of exposure to SSRI s 7349 (27%) individuals experienced significant toxic effects 93 (0.4%) total deaths Linezolid and Serotonin Syndrome Multiple retrospective case studies exist Taylor and colleagues performed retrospective chart review of inpatients at Mayo Clinic 72 patients received concomitant linezolid and an SSRI/SNRI within 14 days of one another 52(72%) patients received concomitant 20(28%) patients received linezolid within 14 day period 2(3%) patients had high probability of serotonin syndrome based on criteria used by Boyer and colleagues Boyer EW, et al.nejm. 2005;352: Taylor JJ, et al. 2006;43(2): Boyer EW, et al. NEJM. 2005;352: Back to the Patients. 35 yo M currently 65 yo M currently admitted for a severe SSTI admitted for a severe SSTI to be started on Linezolid to be started on Linezolid 600mg BID 600mg BID PMH: Depression, back PMH: Depression, chronic pain (post spine surg) pain (NSLC), CHF, DM Current meds: Current meds: Sertraline 100mg D Sertraline 50 mg D Tramadol 100 q 6 h Fentanyl patch 25mg Lasix 20 mg D Metoprolol 100mg D Lisinopril 20mg D Metformin 1000mg BID Glipizide 5mg D What would you do for each patient? Pharmacists Under Fire: What Has Been Done Companies have invested and upgraded their computer alert systems to better protect patients Provided additional training for thousands of its pharmacists New law enacted 14
15 The New Law for Illinois Effective August 18, 2017, the Illinois Department of Financial and Professional Regulation, adopted new rules related to patient counseling that will affect the practice of pharmacy Required to provide verbalcounseling priorto dispensing a medication: To a new patient For an existing patient: New Drug Used to be required to offer counseling but now you are required to counsel Any changes in route, dose, strength and directions Under the new rules, an offer to provide counseling must still be made on all other prescriptions where counseling is not mandated. Summary Some drug interaction are fluid Always depends on the patient Data is changing for some of these interactions Eg-OC s and PCN s If still unsure or literature is confusing, can always call a pharmacy specialist Know your limitations Clinically Significant Drug Interactions: the Antimicrobial Version Viki Barr PharmD, BCPS-AQ ID Assistant Professor Rosalind Franklin University viktorija.barr@rosalindfranklin.edu 15
Clinically Significant Drug Interactions: the Antimicrobial Version. Viki Barr PharmD, BCPS- AQ ID Assistant Professor Rosalind Franklin University
Clinically Significant Drug Interactions: the Antimicrobial Version Viki Barr PharmD, BCPS- AQ ID Assistant Professor Rosalind Franklin University Dr. Barr declares no conflicts of interest, real or apparent,
More informationA Year in Review: Novel Drug Approvals and Important FDA Safety Communications for the Year 2016
A Year in Review: Novel Drug Approvals and Important FDA Safety Communications for the Year 2016 Steven F. Nerenberg, Pharm.D. Clinical Assistant Professor Emergency Medicine Pharmacist Rutgers, The State
More informationTravel Health Conference. April 27, 2018 Jamie Falk, BScPharm, PharmD
Travel Health Conference April 27, 2018 Jamie Falk, BScPharm, PharmD Presenter: Jamie Falk Drug interactions in travelers with chronic conditions I have no conflicts to disclose By attending this session
More informationVolume 9, Number 14 September 2015
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationDrug induced QT prolongation and Torsades de Pointes (TdP) Mark Friesen, PharmD March 13, 2013
Drug induced QT prolongation and Torsades de Pointes (TdP) Mark Friesen, PharmD March 13, 2013 None Conflict of Interest TdP: Learning objectives To review the pathophysiology of QT prolongation and TdP
More information12/19/16. Disclosures
@atriumrx Don t Miss a Beat! Practical Tips on Managing Drug-Induced QTc Prolongation Sandeep Devabhakthuni, PharmD, BCPS- AQ Cardiology Assistant Professor University of Maryland School of Pharmacy Disclosures
More informationAntiarrhythmics & QT Prolongation: Avoiding Drug Interactions
Antiarrhythmics & QT Prolongation: Avoiding Drug Interactions M E L I N D A D E U B N E R, P H A R M D, B C C C P A w e b i n a r f o r H e a l t h T r u s t m e m b e r s A u g u s t 2 4, 2 0 1 8 Disclosures
More informationThe Case of Libby Zion and Dangerous Drug Interactions
The Case of Libby Zion and Dangerous Drug Interactions J.R.White, PA, PharmD I. MAOI and Meperidine Libby Zion 18 yo female Rx c phenelzine (Nardil) Meperidine given for shaking chills Outcome Death Libby
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationTABLE OF CONTENTS. COX-2 Inhibitors Cardiovascular and Gastrointestinal Safety
TABLE OF CONTENTS COX-2 Inhibitors - Cardiovascular and Gastrointestinal Safety 1-2 Oral Erythromycin and Risk of Sudden Cardiac Death 2-3 Common Drug Interactions between Herbal and Prescription Medications
More informationPotential Drug Dosing Variability in Women. Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital
Potential Drug Dosing Variability in Women Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital 2 Objectives Understand the pharmacokinetic variability
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationMitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly
Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly Mary Lynn McPherson, PharmD, MDE, MA, BCPS, CPE Professor and Executive Director, Advanced Post-Graduate
More informationPharmacotherapy Issues in the Pediatric Population
Pharmacotherapy Issues in the Pediatric Population Continuing Professional Pharmacy Development Dr. Shane Pawluk, PharmD Dr. Andrea Cartwright, PharmD Dr. Maryam Khaja March 26, 2014 Outline Didactic Session
More information2. Is this request for a preferred medication? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationDrug Therapy Following Bariatric Surgery
Drug Therapy Following Bariatric Surgery Linda F. McElhiney PharmD, RPh, MSP, FIACP, FACA, FASHP, DPLA Compounding Pharmacist Indiana University Health Disclosures Dr. McElhiney declare(s) no conflicts
More informationANSWER # 1 PHARMACOLOGY. Methadone answers Stoltzfus 4/5/2012 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017
METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017 Ky Stoltzfus, MD Assistant Professor, Internal Medicine University of Kansas Medical Center ANSWER # 1 Your response might be
More informationDrug Prescribing. Ravi Menon
Drug Prescribing Ravi Menon Introduction Approximately 7,000 individual drug doses are administered each day in a 'typical' NHS hospital, 70% of which are prescribed by first year graduates and senior
More informationPharmacology 101: Anti-Epileptic Drugs
Pharmacology 101: Anti-Epileptic Drugs DSF Biennial Family Conference July 21, 2018 Michelle Welborn, PharmD Objectives Receive Practical Advice Regarding Prescription Medications Understand the Absorption,
More informationThe general Concepts of Pharmacokinetics
The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique
More informationA. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention
DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention
More informationCharles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center
Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Kathy Peters is a 63 y.o. patient that presents to your urgent care office today with a history
More informationTomasz Z. Jodlowski, Pharm.D., BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases VA North Texas HCS
Tomasz Z. Jodlowski, Pharm.D., BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases VA North Texas HCS Tomasz.Jodlowski@va.gov 02/06/2018 Independent contractor. IPRO. IPRO Antibiotic Stewardship
More information3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationAbiraterone Acetate is an antiandrogen used in the treatment of Castration-Resistant Prostate Cancer(CRPC).
For the use only of an Oncologist or a Hospital or a Laboratory ABIRATERONE ACETATE TABLETS Zabiteron-250 COMPOSITION Abiraterone Acetate Tablets 250mg Each uncoated tablets contains: Abiraterone Acetate
More informationDavid Dosa MD, MPH Assistant Professor of Medicine and Community Health The Warren Alpert School of Medicine, Brown University Director, Primary Care
David Dosa MD, MPH Assistant Professor of Medicine and Community Health The Warren Alpert School of Medicine, Brown University Director, Primary Care Geriatrics Clinic- Providence VAMC VA Grand Rounds
More informationPrescribing spironolactone for acne. Julie C Harper MD
Prescribing spironolactone for acne Julie C Harper MD Conflict of Interest Disclosure none Spironolactone FDA-approval in 1960 Current FDA-approved indications: Primary hyperaldosteronism Edematous conditions
More informationA Step Forward: Promoting Independence through Falls Prevention
A Step Forward: Promoting Independence through Falls Prevention 2014 Geriatric Update Meharry Consortium Geriatric Education Center A Step Forward: Promoting Independence through Falls Prevention Moderator:
More informationClinical Pharmacology and Prescribing
1 Clinical Pharmacology and Prescribing Dr Susannah O Sullivan Department of Pharmacology 2 Objectives Recognise the importance of clinical pharmacology as the scientific discipline that underpins a rational
More informationCELEXA (CITALOPRAM) UTILIZATION AND DOSING MANAGEMENT
BACKGROUND CELEXA (CITALOPRAM) UTILIZATION AND DOSING MANAGEMENT In May 2007, the FDA issued a notice that the agency was updating the black box warning for antidepressants to include warnings about increased
More informationRhythm and Blues Drugs and QT Prolongation
Rhythm and Blues Drugs and QT Prolongation Dr Martin Quinn St Vincents University Hospital Irish Medication Safety Network conference Farmleigh 18 Oct 2013 Drugs and QT Prolongation Anti-psychotic, antidepressant,
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationSummary of the risk management plan (RMP) for Zykadia (ceritinib)
EMA/154751/2015 Summary of the risk management plan (RMP) for Zykadia (ceritinib) This is a summary of the risk management plan (RMP) for Zykadia, which details the measures to be taken in order to ensure
More informationIBRANCE (palbociclib) oral capsule
IBRANCE (palbociclib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationHow do we define pneumonia?
Robert L. Keith MD FCCP Associate Professor of Medicine Division of Pulmonary Sciences & Critical Care Medicine Denver VA Medical Center University of Colorado Denver How do we define pneumonia? Fever
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationPACKAGE LEAFLET: Information for the user. METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride)
PACKAGE LEAFLET: Information for the user METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride) Read this leaflet carefully before you start taking this medicine. - Keep this
More informationQT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency
QT prolongation and drug-drug interactions Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency Disposition Introduction to QT prolongation Three relevant DDI scenarios Concluding
More informationKiller Drug Interactions. Karen Curzio Rodeghiero, PharmD, BCPS Clinical Pharmacist, Emergency Medicine Piedmont Athens Regional
Killer Drug Interactions Karen Curzio Rodeghiero, PharmD, BCPS Clinical Pharmacist, Emergency Medicine Piedmont Athens Regional Disclosure I have no financial interests or relationships to disclose Primum
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT TIKOSYN 125 microgram hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 125 micrograms of dofetilide
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful
More informationPharmacology in the Elderly
Pharmacology in the Elderly James Hardy Geriatrician, Royal North Shore Hospital A recent consultation Aspirin Clopidogrel Warfarin Coloxyl with senna Clearlax Methotrexate Paracetamol Pantoprazole Cholecalciferol
More informationBackground. Background. Background 3/14/2014. Conflict of Interest Statement:
Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationMedication Safety Tips. Gerry Maloney, DO, CPPS Dept of Emergency Medicine CWRU/MetroHealth Medical Center
Medication Safety Tips Gerry Maloney, DO, CPPS Dept of Emergency Medicine CWRU/MetroHealth Medical Center None Disclosures Objectives Discuss the evolution of the patient safety movement and its implications
More informationPsychotropic Medications: What s New?
Psychotropic Medications: What s New? Stacie L Penkova, PharmD, MHSA, BCPS Acclaim Pharmacy Benefits Manager Connected Care Partners Project Manager Outcomes Conference August 2016 Disclosures I, Stacie
More informationCommunity Acquired Pneumonia. Background & Rationale to North American Guidelines. Lionel Mandell MD FRCPC Brussels Belgium
Community Acquired Pneumonia Background & Rationale to North American Guidelines Lionel Mandell MD FRCPC Brussels Belgium Consider Impact of the disease Issues to reflect upon Impact of the Disease 3-4
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationDRUG INTERACTIONS WITH WARFARIN 27 OCTOBER 2018
DRUG INTERACTIONS WITH WARFARIN 27 OCTOBER 2018 Types of Warfarin Drug Interactions Pharmacodynamics: Antiplatelets NSAIDs Vitamin K production (Antimicrobials) Pharmacokinetics: Protein displacement CYP450
More informationDisclosures. Patient Case. Learning Objectives. Prevalence. Patient Case, cont. 8/2/2014. Clinical Pearls: Significant Drug Interactions
Disclosures Nothing to disclose Clinical Pearls: Significant Drug Interactions Teresa Kam, PharmD, CPP University of North Carolina Medical Center Learning Objectives Describe the classifications of drug
More informationDiabetes and the Elderly: Medication Considerations When Determining Benefits and Risks
Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES
More informationLet s Interact A Discussion on Managing Drug Interactions in Oncology
Let s Interact A Discussion on Managing Drug Interactions in Oncology Pat Trozzo Kristi Hofer Presenter Disclosure Faculty: Kristi Hofer Relationships with commercial interests: Grants/Research Support:
More information3. P450 Drug Metabolism DDIs: Induction
35 3. P450 Drug Metabolism DDIs: Induction General Introductiona and Definition of a DDI: A drug-drug interaction (DDI) occurs when two drugs, each of which is safe and efficacious alone at their respective
More informationVELTASSA (patiromer) oral suspension
VELTASSA (patiromer) oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationApplication of Evidence Based, Patient Specific Drug Interaction Screening
Application of Evidence Based, Patient Specific Drug Interaction Screening John R. Horn, PharmD, FCCP Professor of Pharmacy, School of Pharmacy Associate Director UW Medicine Pharmacy Services University
More informationCiprofloxacin does not Prolong the QTc Interval: A Clinical Study in ICU Patients and Review of the Literature
Ciprofloxacin does not Prolong the QTc Interval: A Clinical Study in ICU Patients and Review of the Literature Charlotte PM Heemskerk a,b, Evelien Woldman a,c, Marieke Pereboom a, Ruud TM van der Hoeven
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationPain Management Management in Hepatic Hepatic and and Renal Dysfunction
Pain Management in Hepatic and Renal Dysfunction Review the pharmacologic basis for medications used in pain management Identify pain medications which hshould ldbe avoided in patients with hepatic dysfunction
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti-Cancer Treatment Protocol. Abiraterone. PROCTOCOL REF: MPHAABIRA (Version No: 1.
Systemic Anti-Cancer Treatment Protocol Abiraterone PROCTOCOL REF: MPHAABIRA (Version No: 1.0) Approved for use in: The treatment of metastatic castration resistant prostate cancer in adult men who are
More informationHot Topics: Transitions of Care
Our quarterly newsletter is a great way to stay up-to-date on emerging clinical information, medication safety issues, and Larkin s Hospital medication policies and procedures. Hot Topics: Transitions
More informationMethadone Maintenance
Methadone Maintenance A Practical Guide to Pharmacotherapy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Ron Joe, MD, DABAM Objectives I. Pharmacology Of Methadone II. Practical Application of Pharmacology
More informationStudy Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg;
The study listed may include approved non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCases of Patients with OUD. Objectives
Cases of Patients with OUD Soraya Azari, MD Objectives To dive further into cases of patients related to OUD, including some more challenging cases from the inpatient setting. To refine your skills at
More informationFluoroquinolone-Associated Disability (FQAD) Cases in Patients Being Treated for Uncomplicated Sinusitis, Bronchitis, and/or Urinary Tract Infection
Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee November 5, 2015 FDA s Adverse Event Reporting System (FAERS) Review: Fluoroquinolone-Associated
More informationPrinciples of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND
Principles of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND Financial Disclosure None of the planners, speakers, and/or members of the CME committee
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationeview Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP yright t for Sale or Commercial Distribution
Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP Presented at the University of Saskatchewan s 4th Annual Peter and Anna Zbeetnoff Memorial Drug Therapy Decision-Making Conference,
More informationMEDCHEM 562. Physicochemical Properties of Drugs: Lecture 2; Kent Kunze. Stereochemistry (Double the trouble. or double the fun?)
1 MEDCHEM 562 Physicochemical Properties of Drugs: Lecture 2; Kent Kunze Stereochemistry (Double the trouble. or double the fun?) The vast majority of drugs contain at least one stereo-center or site of
More informationDsuvia (sufentanil) NEW PRODUCT SLIDESHOW
Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,
More informationDrug CHAPTER 2. Pharmacologic Principles. NDEG 26A Eliza Rivera-Mitu, RN, MSN. Pharmacology. Drug Names. Pharmacologic Principles. Drug Names (cont'd)
CHAPTER 2 Pharmacologic Principles NDEG 26A Eliza Rivera-Mitu, RN, MSN Drug Any chemical that affects the physiologic processes of a living organism Pharmacology The study or science of drugs Drug Names
More informationPrimary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017
John Briles, MD, Medical Director October 11, 2017 Molina Healthcare of Michigan uses a HEDIS measure for Antidepressant Medication Management (AMM) to measure how well treating providers (PCPs) appropriately
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN. LYSODREN (mitotane)
More informationAustedo. (deutetrabenazine) New Product Slideshow
Austedo (deutetrabenazine) New Product Slideshow Introduction Brand name: Austedo Generic name: Deutetrabenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and
More informationONCE-DAILY DOSING WITH NUPLAZID
YOUR GUIDE TO ONCE-DAILY DOSING WITH NUPLAZID NUPLAZID (pimavanserin) is the first and only FDAapproved treatment for hallucinations and delusions associated with Parkinson s disease psychosis 1 Indication
More informationOpioid Overdose Best Practices Guideline. Table of Contents. A. General description: B: Typical signs and symptoms:
Opioid Overdose Best Practices Guideline Table of Contents A. General description B. Typical signs and symptoms C. Expected course D. Making the diagnosis E. Recommended treatment F. Criteria for hospital
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationNew Guidelines for Opioid Prescribing
New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationPractical Guide to Safety of PPIs What to Tell Your Patient. Proton Pump Inhibitors
Practical Guide to Safety of PPIs What to Tell Your Patient Joel E Richter, MD, FACP, MACG Professor and Director Division of Digestive Diseases and Nutrition Joy Culverhouse Center for Esophageal Diseases
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationDrug Interactions and Prescribing Errors
Drug Interactions and Prescribing Errors John R. Horn, PharmD, FCCP Professor of Pharmacy, School of Pharmacy Associate Director UW Medicine Pharmacy Services University of Washington Seattle, WA Financial
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More information5-HT 3 -receptor antagonists
5-HT 3 -receptor antagonists 5-HT 3 -receptor antagonists 5-HT 3 -receptor antagonists + Opioids Ondansetron reduces the analgesic efficacy of tramadol and at least double the dose was required in one
More informationMedication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets
Medication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets Read the Medication Guide that comes with SARAFEM before you start taking it and each time you get a refill. There may be new information.
More informationIntroduction to Pharmacology: Pearls and Tidbits for the Dravet Community
Introduction to Pharmacology: Pearls and Tidbits for the Dravet Community 2016 Dravet Syndrome Foundation Biennial Family& Professional Conference June 25, 2016 Coral Gables, FL Michelle Welborn, PharmD
More informationClinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid
Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and
More informationMISCELLANEOUS AGENTS - ALPHA-AGONISTS
Documentation A. FDA Approved Indications ADHD (Clonidine, Guanfacine) Documentation B. Non-FDA approved, commonly used psychiatric indications 1. Alcohol and opiate dependence 2. Opioid withdrawal 3.
More informationClinical Policy: Vilazodone (Viibryd) Reference Number: CP.PMN.145 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Viibryd) Reference Number: CP.PMN.145 Effective Date: 08.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationFurosemide: Properties, Alternatives, and the Medication Approval Process. Heather Brown EMS 209-Advanced Pharmacology Don Knox
Furosemide: Properties, Alternatives, and the Medication Approval Process Heather Brown EMS 209-Advanced Pharmacology Don Knox Pre-hospital treatment of critical patients is a key factor in determining
More information